Yourgene Health plc
("Yourgene Health" or the "Company")
Issue of Share Options
Manchester, UK - 3 June 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the issuance of share options in connection with the recent fundraise.
Further to the announcement on 17 April 2019, the Company has issued 10,590,000 share options to certain Directors of Yourgene Health and certain members of the senior management team of the enlarged Yourgene Health group (the "New Options"). The numbers of New Options issued to Directors and PDMRs are shown in the table below:
|
Name |
Options held prior to the current issue |
Number of New Options issued |
Total number of options held |
|
Lyn Rees |
10,000,000 |
4,000,000 |
14,000,000 |
|
Barry Hextall |
5,000,000 |
400,000 |
5,400,000 |
|
Bill Chang |
700,000 |
400,000 |
1,100,000 |
|
Hayden Jeffreys |
3,000,000 |
2,400,000 |
5,400,000 |
The exercise price of the New Options is 10.25 pence and the New Options vest over three years, in equal annual tranches, subject to performance criteria based on EPS growth. In total, the New Options represent approximately 1.8 per cent. of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
|
For more information, please contact:
|
|
|
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing
|
Tel: +44 (0)161 667 1053
|
|
Cairn Financial Advisers LLP (Nomad) Liam Murray / James Caithie / Ludovico Lazzaretti
|
Tel: +44 (0)20 7213 0880 |
|
Stifel Nicolaus Europe Limited (Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison
|
Tel: +44 (0)20 7710 7600 |
|
Vigo Communications (PR) Ben Simons / Fiona Henson / Antonia Pollock |
Tel: +44 (0)20 7390 0238
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
a) Lyn Rees b) Barry Hextall c) Bill Chang d) Hayden Jeffreys |
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
a) CEO b) CFO c) CSO d) COO |
|||||
|
b. |
Initial notification/ Amendment |
Initial notification |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Yourgene Health plc |
|||||
|
b. |
LEI |
213800UUIT8BZE7QEH33 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over ordinary shares of 0.10p each
ISIN: GB00BN31ZD89 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
a) 10.25 b) 10.25 c) 10.25 d) 10.25 |
a) 4,000,000 b) 400,000 c) 400,000 d) 2,400,000 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
31 May 2019 |
|||||
|
f. |
Place of the transaction |
UK |
|||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
